Expert perspectives on cholangiocarcinoma (CCA)

Intended for European healthcare professionals only

Cholangiocarcinoma: Under the spotlight

This online webinar took place on 26 February 2021 and was hosted by our esteemed faculty
who critically discussed the complexity of diagnosing CCA and the clinical and genetic
heterogeneity associated with the disease.

Dr Teresa Macarulla

Vall d’Hebron University Hospital,
Barcelona, Spain

Dr Joachim Mertens

University Hospital Zürich,
Zürich, Switzerland

Dr Angela Lamarca

The Christie NHS Foundation Trust,
Manchester, UK

Dr Coralie Sayag

Medical Director Solid Tumors, Region Europe,
Incyte Biosciences International Sàrl

Educational highlights and quiz

Watch the five educational videos below and answer the quiz questions to enhance your knowledge of CCA.

Overview of CCA

Professor Bruno Sangro

Director, Liver Unit & Co-Director, HPB Oncology Area,
Clinica Universidad de Navarra, Pamplona, Spain

Although rare, the incidence of CCA, in particular intrahepatic CCA, is generally increasing worldwide

REFERENCE: Bañales JM, et al. Nat Rev Gastroenterol Hepatol. 2016;13:261–80.

Download PDF

Answer the question below

Approximately, what is the 5-year overall survival rate for patients with CCA? (Select one)

Unmet needs in CCA

Helen Morement

CEO and Founder of AMMF - The Cholangiocarcinoma Charity, London, UK

70% of patients with CCA are diagnosed with advanced disease, which compromises therapeutic options and leads to a poor prognosis

REFERENCE: Bañales JM, et al. Nat Rev Gastroenterol Hepatol. 2020;17:557–88.

Download PDF

Answer the question below

What key unmet needs are associated with CCA? (Select all that apply)

Importance of the multidisciplinary team (MDT)
in CCA diagnosis and treatment

Professor Lorenza Rimassa

Associate Professor of Medical Oncology, Humanitas University and Humanitas Research Hospital-IRCCS, Milan, Italy

Helen Morement

CEO and Founder of AMMF - The Cholangiocarcinoma Charity, London, UK

Professor Juan Valle

University of Manchester/The Christie, Manchester, UK

Professor Peter Schirmacher

Institute of Pathology, University Hospital Heidelberg

A multidisciplinary team approach enables a more comprehensive understanding of disease biology and collaboration options for patients with CCA

REFERENCE: Patel T. Nat Rev Gastroenterol Hepatol. 2011;8:189–200.

Download PDF

Answer the question below

Patients with CCA are often misdiagnosed with cancers of unknown primary – true or false?

Importance of performing biopsies in patients with CCA

Professor Lorenza Rimassa

Associate Professor of Medical Oncology, Humanitas University and Humanitas Research Hospital-IRCCS, Milan, Italy

Helen Morement

CEO and Founder of AMMF - The Cholangiocarcinoma Charity, London, UK

Professor Juan Valle

University of Manchester/The Christie, Manchester, UK

Professor Peter Schirmacher

Institute of Pathology, University Hospital Heidelberg

Biopsy technique should account for planned molecular profiling as well as diagnostic needs

REFERENCE: Cree IA, et al. J Clin Pathol. 2014;67:923–31

Download PDF

Answer the question below

What percentage of patients with CCA present with advanced disease, for which a biopsy should be considered mandatory? (Select one)

Importance of molecular profiling in patients with CCA

Professor Lorenza Rimassa

Associate Professor of Medical Oncology, Humanitas University and Humanitas Research Hospital-IRCCS, Milan, Italy

Helen Morement

CEO and Founder of AMMF - The Cholangiocarcinoma Charity, London, UK

Professor Juan Valle

University of Manchester/The Christie, Manchester, UK

Professor Peter Schirmacher

Institute of Pathology, University Hospital Heidelberg

50% of patients with CCA have at least one potentially actionable genomic alterations, supporting the rationale for molecular profiling at diagnosis

REFERENCE: Lowery MA, et al. Clin Cancer Res. 2018;24:4154–61.

Download PDF

Answer the question below

For which patients with CCA should molecular profiling be considered? (Select all that apply)

Disclosures

Teresa Macarulla:

Company/Organisation	Relationship(s)
Personal financial interests:
Amgen, Servier, Incyte, Sanofi, Celgene, AstraZeneca	Advisory role
Celgene, Servier, Incyte, Amgen, Sanofi	Speaker’s fee
Celgene, AstraZeneca, BeiGene	Direct research fund
Institutional financial interests:
AstraZeneca, Q&D, Incyte, Tahio, Genentech, Celgene, MSD, Novocure, BeiGene	Clinical trial support

Joachim Mertens:

Company/Organisation	Relationship(s)
Bristol Myers Squibb, Bayer, Eisai, Gilead, Incyte, Intercept, Ipsen, MDS, Roche, Sanofi, Sigma-Tau	Consulting honoraria and advisory boards

Angela Lamarca:

Company/Organisation	Relationship(s)
Eisai, Nutricia, Ipsen, QED	Speakers bureau
Pfizer, Ipsen, Merck, Incyte	Participation in company sponsored speaker bureau
Ipsen, Pfizer, Bayer, AAA, Sirtex, Delcath, Novartis, Mylan	Travel, education funding

Coralie Sayag:

Company/Organisation	Relationship(s)
Incyte Biosciences International Sàrl	Employee

Disclosures

Bruno Sangro:

Company/Organisation	Relationship(s)
Adaptimmune, Bayer, Bristol Myers Squibb, H3 Biomedicine, Ipsen, Lilly, Merck, Onxeo, Roche, Sirtex medical	Consulting, advisory role or honoraria
Bristol Myers Squibb, Onxeo, Sirtex Medical	Grants

Disclosures

Helen Morement:

Company/Organisation	Relationship(s)
Incyte	Speaker

Disclosures

Lorenza Rimassa:

Company/Organisation	Relationship(s)
Amgen, ArQule, AstraZeneca, Basilea, Bayer, Celgene, Eisai, Exelixis, Hengrui, Incyte, Ipsen, Lilly, Merck Sharp & Dohme, Nerviano Medical Sciences, Roche, Sanofi	Consulting/Advisory role
AbbVie, Amgen, Eisai, Gilead, Incyte, Ipsen, Lilly, Roche, Sanofi	Honoraria/Lectures
Ipsen	Travel expenses
Agios, ARMO BioSciences, AstraZeneca, BeiGene, Eisai, Exelixis, Fibrogen, Incyte, Ipsen, Lilly, Merck Sharp & Dohme, Roche	Research funding to institution

Helen Morement:

Company/Organisation	Relationship(s)
Incyte	Speaker

Juan Valle:

Company/Organisation	Relationship(s)
Imaging Equipment Ltd, Ipsen, Novartis, NuCana	Speakers bureau
Celgene, NuCana	Travel Grant
Agios, AstraZeneca, Debiopharm, Delcath Systems, GenoScience Pharma, Imaging Equipment Ltd, Incyte, Ipsen, Keocyt, Merck, Mundipharma EDO, Novartis, NuCana, PCI Biotech, Pieris Pharmaceuticals, Pfizer, QED, Servier, Wren Laboratories	Grant support

Peter Schirmacher:

Company/Organisation	Relationship(s)
AstraZeneca, Incyte, Janssen, Novartis, Roche	Speakers bureau
Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Incyte, Janssen, Merck Sharp & Dohme, Novartis, Roche	Board
AstraZeneca, Bristol Myers Squibb, Illumina, Novartis	Grant support

If you would like to request further medical information, please visit:
www.incyteglobalmedicalinformation.com

* This webpage contains information based on speakers' own professional experience.

Expert perspectives on CCA page

AT/PEMA/NP/21/0002
UK/PEMA/NP/21/0005
EU/PEMA/NP/21/0002
NL/PEMA/NP/21/0007
ES/PEMA/NP/21/0003
DK/PEMA/NP/21/0011
CH/PEMA/NP/21/0001
DE/PEMA/NP/21/0007
BE/PEMA/NP/21/0011

Cholangiocarcinoma: Under the spotlight

AT/PEMIFGFR/NP/21/0010
UK/PEMA/NP/21/0006
EU/PEMA/NP/21/0003
NL/PEMA/NP/21/0008
ES/PEMA/NP/21/0004
DK/PEMA/NP/21/0012
CH/PEMA/NP/21/0002
DE/PEMA/NP/21/0008
BE/PEMA/NP/21/0012

Overview of CCA

DK/PEMA/NP/21/0006
BE/PEMA/NP/21/0013

Unmet needs in CCA

DK/PEMA/NP/21/0007
BE/PEMA/NP/21/0014

Importance of the multidisciplinary team (MDT) in CCA diagnosis and treatment

DK/PEMA/NP/21/0008
BE/PEMA/NP/21/0015

Importance of performing biopsies in patients with CCA

DK/PEMA/NP/21/0009
BE/PEMA/NP/21/0016

Importance of molecular profiling in patients with CCA

DK/PEMA/NP/21/0010
BE/PEMA/NP/21/0017

If you would like to request further medical information, please visit:
www.incyteglobalmedicalinformation.com